Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 167
Filtrar
1.
Braz. dent. sci ; 24(3): 1-8, 2021. tab
Artículo en Inglés | LILACS, BBO | ID: biblio-1281176

RESUMEN

Objetivo: Avaliar os efeitos bioquímicos e histopatológicos da administração de diclofenaco e cetoprofeno na regeneração óssea em modelo de defeito calvarial em ratos. Material e Métodos: A amostra foi composta por 108 ratos Wistar que foram distribuídos aleatoriamente em três grupos, aos quais foi realizada osteotomia de 6 mm de diâmetro na calvária. O grupo A (controle) recebeu solução salina; O Grupo B recebeu 2 mg / kg de cetoprofeno e o Grupo C recebeu 2 mg / kg de diclofenaco. Todos os tratamentos foram administrados intraperitonealmente a cada 12 horas durante 3 dias. A regeneração óssea foi avaliada pelas características bioquímicas (fosfatase alcalina e cálcio sérico) e histopatológicas (contagem de osteócitos e células de osteoblastos) aos 15 e 30 dias. Resultados:Na avaliação bioquímica, os níveis de fosfatase alcalina no grupo cetoprofeno foram significativamente menores em comparação com o grupo diclofenaco em 15 e 30 dias (p= 0.015 e p= 0.001; respectivamente). No entanto, os níveis séricos de cálcio não mostraram diferença entre os grupos de estudo aos 15 e 30 dias (p= 0.42 p= 0.81; respectivamente). Na análise histopatológica, a contagem de osteoblastos e osteócitos foi significativamente menor no grupo cetoprofeno em comparação ao grupo diclofenaco aos 15 e 30 dias (p< 0,05). Conclusão: A administração de cetoprofeno tem efeitos bioquímicos e histopatológicos negativos de maior intensidade na regeneração óssea em comparação com a administração de diclofenaco. (AU)


Objective: To evaluate the biochemical and histopathological effects of diclofenac and ketoprofen administration on bone regeneration in a calvarial defect model in rats. Material and Methods: The sample consisted of 108 Wistar rats that were randomly distributed in three groups, to which an osteotomy of 6 mm in diameter was performed in the calvaria. Group A (control) was given saline solution; Group B received ketoprofen 2 mg/kg and Group C received diclofenac 2 mg/kg. All treatments were administered intraperitoneally every 12 hours for 3 days. Bone regeneration was evaluated by biochemical (alkaline phosphatase and serum calcium) and histopathological (osteocyte and osteoblast cell count) characteristics at 15 and 30 days. Results: In the biochemical evaluation, alkaline phosphatase levels in the ketoprofen group were significantly lower compared to the diclofenac group at 15 and 30 days (p= 0.015 and p= 0.001; respectively). However, serum calcium levels did not show the difference between the study groups at 15 and 30 days (p= 0.42 and p= 0.81; respectively). In the histopathological analysis, the count of osteoblasts and osteocytes was significantly lower in the ketoprofen group compared to the diclofenac group at 15 and 30 days (p< 0.05). Conclusion: The administration of ketoprofen has negative biochemical and histopathological effects of greater intensity on bone regeneration compared to the administration of diclofenac (AU)


Asunto(s)
Animales , Ratas , Ratas , Regeneración Ósea , Antiinflamatorios no Esteroideos , Diclofenaco , Cetoprofeno
2.
Pesqui. vet. bras ; 41: e06652, 2021. tab, graf, ilus
Artículo en Inglés | LILACS, VETINDEX | ID: biblio-1180875

RESUMEN

Painful procedures can affect the function of innate immune cells, such as neutrophils and macrophages, increasing the risk of infectious diseases. The present work aimed to verify if the analgesics flunixin meglumine or ketoprofen can attenuate the pain/discomfort of newborn lambs submitted by elastration tail docking and thereby avoid the impairment of blood granulocytes function. Twenty-one neonate lambs were divided into three treatments: the control group (n=7), not subjected to caudectomy; the flunixin group (n=7), subjected to caudectomy under local anesthesia and analgesia with two doses of flunixin meglumine; and the ketoprofen group (n=7), subjected to caudectomy under local anesthesia and two doses of ketoprofen. Pain indicators were observed by pain posture score (PS), the number of vocalizations (V), frequency of the movement of the ears (EF), and respiratory rates (RR), observed by a 10 minutes videos for each time points: -15min, 6h, 48h, and 144h. At the same time points, the reactive oxygen species (ROS) production and phagocytosis of blood granulocytes were measured by flow cytometry. At 6h after caudectomy, there was a pain indicator increase (RR, V, and PS), a blood granulocyte percentage increase, and a granulocytes phagocytosis reduction for both groups. At 48h, the ketoprofen group spend more time in pain posture and, at 144h, they exhibited a ROS production granulocyte reduction without signs of pain. We conclude the flunixin meglumine and ketoprofen did not prevent the acute pain/discomfort caused by caudectomy, because the groups showed a pain behavior and impaired of the innate immune response however, the flunixin meglumine was effective in controlling the chronic pain and their effects on blood granulocytes function in compare ketoprofen.(AU)


Procedimentos dolorosos podem afetar a função das células imunes inatas como neutrófilos e macrófagos, aumentando o risco de ocorrer doenças infeciosas. Desta maneira, o presente trabalho pretendeu verificar se os analgésicos flunixin meglumine ou cetoprofeno conseguem atenuar a dor/desconforto de cordeiros neonatos submetidos a caudectomia por elastração, evitando assim o comprometimento da função dos granulócitos sanguíneos. Para tanto 21 cordeiras foram aleatoriamente divididas em três tratamentos: grupo controle (n=7) não submetido a caudectomia, grupo flunixin (n=7) submetido a caudectomia precedida por anestesia local e duas doses de flunixin meglumine, e cetoprofeno (n=7) submetido a caudectomia precedida por anestesia local e duas doses de cetoprofeno. Mensurou-se os indicadores de dor/desconforto após caudectomia por observações de escore de postura de dor (EP), número de vocalizações (V), frequência de movimentar as orelhas (FO) e frequência respiratória (FR), observados em vídeos de 10 minutos nos momentos -15 min e 6, 48 e 144h. Nos mesmos momentos, avaliou-se a as funções de produção de espécies reativas de oxigênio (ERO) e de fagocitose por granulócitos sanguineos em citometria de fluxo. Notou-se aumento dos indicadores de dor (FR, de V e de EP), da porcentagem dos granulócitos sanguíneos e redução da eficiência de fagocitose em ambos os grupos as 6h. As 48h, os animais do grupo cetoprofeno ainda apresentava mais tempo em postura de dor que os demais grupos e as 144h, apresentou redução da produção ERO por granulócitos. Tais achados permitem concluir que tanto o flunexin meglumine como o cetoprofeno não preveniram dor/desconforto agudo promovido pela elastração, pois os dois grupos manifestaram comportamento de dor e redução da resposta imune inata. Ainda, o analgésico flunixin meglumine foi efetivo em controlar a dor mais tardia e seus efeitos na função de granulócitos sanguíneos em comparação ao cetoprofeno.(AU)


Asunto(s)
Animales , Femenino , Fagocitosis , Ovinos , Cetoprofeno , Analgesia , Neutrófilos , Especies Reactivas de Oxígeno
3.
Int. j. morphol ; 38(3): 523-529, June 2020. graf
Artículo en Inglés | LILACS | ID: biblio-1098282

RESUMEN

This study aimed to investigate the morphometric and the pattern of protein and gene expression related to the extrinsic apoptotic pathway in experimental focal cerebral ischemia and the hole of neuroprotection with hypothermia and ketoprofen. For this analysis, 120 rats were randomly divided into 3 groups (20 animals each): control - no surgery (20 animals); sham - simulation of surgery (20 animals); ischemic - focal ischemia for 1 hour, without reperfusion (80 animals) and divided into four subgroups with 20 animals each: ischemic + intraischemic hypothermia; ischemic + previous intravenous ketoprofen, and ischemic + hypothermia and ketoprofen. The infarct volume was measured using morphometric analysis of infarct areas defined by triphenyl tetrazolium chloride and the patterns of expression of the apoptosis genes (Fas, c-Flip, caspase-8 and caspase-3) and the apoptosis protein caspase-3 were evaluated by quantitative real-time PCR and immunohistochemistry, respectively. Hypo expression of genes of extrinsic pathway of apoptosis was observed: Fas receptor, c-Flip and caspase-8 in the ischemics areas. Increases in the gene and protein caspase-3 in the ischemic areas were also observed, and these increases were reduced by hypothermia and ketoprofen, also noted in the morphometric study. The caspases-3 increase suggests that this gene plays an important role in apoptosis, probably culminating in cell death and that the neuroprotective effect of hypothermia and ketoprofen is involved.


Este estudio tuvo como objetivo investigar la morfometría y el patrón de expresión de proteínas y genes relacionados con la vía apoptótica extrínseca en la isquemia cerebral focal experimental y el agujero de neuroprotección con hipotermia y ketoprofeno. Se dividieron aleatoriamente 120 ratas en 3 grupos (20 animales cada uno): control - sin cirugía (20 animales); simulación - simulación de cirugía (20 animales); isquemia isquemia focal durante 1 hora, sin reperfusión (80 animales) y dividida en cuatro subgrupos con 20 animales cada uno: isquemia + hipotermia intraisquémica; isquemia + ketoprofeno intravenoso previo, e isquemia + hipotermia y ketoprofeno. El volumen del infarto se midió utilizando un análisis morfométrico de áreas de infarto definidas por cloruro de trifenil tetrazolio y los patrones de expresión de los genes de apoptosis (Fas, c-Flip, caspase-8 y caspase-3) y la proteína de apoptosis caspase-3 fueron evaluados por PCR cuantitativa en tiempo real e inmunohistoquímica, respectivamente. Se observó hipoexpresión de genes de la vía extrínseca de la apoptosis: receptor Fas, c-Flip y caspasa-8 en las áreas isquémicas. También se observaron aumentos en el gen y la proteína caspasa-3 en las áreas isquémicas y estos aumentos se redujeron por hipotermia y ketoprofeno, también observado por estudio morfométrico. El aumento de caspasas-3 sugiere que este gen tiene un papel importante en la apoptosis, y probable causa de muerte celular, involucrando el efecto neuroprotector de la hipotermia y el ketoprofeno.


Asunto(s)
Animales , Ratas , Isquemia Encefálica/genética , Isquemia Encefálica/metabolismo , Inmunohistoquímica , Isquemia Encefálica/patología , Isquemia Encefálica/terapia , Cetoprofeno/farmacología , Apoptosis/genética , Fármacos Neuroprotectores/farmacología , Modelos Animales de Enfermedad , Caspasa 3/genética , Caspasa 8/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Hipotermia Inducida
4.
Braz. J. Pharm. Sci. (Online) ; 56: e18641, 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1132037

RESUMEN

The aim of the present study was to enhance the dissolution rate of an NSAID drug Ketoprofen by formulating it into solid dispersions with water soluble carrier Poloxamer 188 and Eudragit S 100. The solid dispersions of Ketoprofen with Poloxamer 188 were prepared at 1:1, 1:1.5 and 1:2 (Ketoprofen: Poloxamer 188) ratio by Solvent evaporation methods. The same concentration ratio was used for the preparation of solid dispersion with Eudragit S 100 by melting/fusion technique. Further, solid dispersions were investigated by solubility, ATR-FTIR, XRD, DSC, surface morphology, in-vitro dissolution and accelerated stability study. Results demonstrated that both Poloxamer 188 and Eudragit S 100 improve solubility of drugs by 8­10 folds. The result of ATR-FTIR study showed the slight shifting/broadening of principle peaks. In vitro dissolution studies showed that in the solid dispersion system containing Ketoprofen: Poloxamer 188 batch P2 (1:1.5) gives faster dissolution rate of Ketoprofen than the physical mixtures. The solid dispersion with Eudragit S 100, batch E1 (1:1) gives faster dissolution rate of Ketoprofen than the physical mixtures. In phase solubility study with Poloxamer 188 showed concentration dependent solubilization of drug but Eudragit S 100 produced opposite result. The effect of pH on solubility of Eudragit S 100 was carried out which showed solubility at pH 7.4. The dissolution profile of solid dispersion with Eudragit S 100 at pH 7.4 gives excellent result. The Accelerated stability of solid dispersions & its physical mixtures were studied at 400±2 °C/75 ± 5% RH for a period of 1 month. In these studies, Solid Dispersion batches produced an unstable formulation. The Ketoprofen solid dispersions with Poloxamer 188 and Eudragit S 100 could be introduced as a suitable form with improved solubility


Asunto(s)
Solubilidad , Cetoprofeno/análogos & derivados , Triaje/clasificación , Poloxámero/análogos & derivados , Técnicas In Vitro , Preparaciones Farmacéuticas/administración & dosificación , Antiinflamatorios no Esteroideos/clasificación , Espectroscopía Infrarroja por Transformada de Fourier , Disolución/análisis , Concentración de Iones de Hidrógeno
5.
Braz. J. Pharm. Sci. (Online) ; 56: e18540, 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1285516

RESUMEN

Dexketoprofen trometamol (DT) is an active S (+) enantiomer of ketoprofen, and a non-steroidal anti-inflammatory agent. DT has a short biological half-life and the dosing interval is quite short when there is a need to maintain the desirable effect for longer time periods. Consequently, a controlled release DT tablet was designed for oral administration aiming to minimize the number of doses and the possible side effects. Calculations of the parameters for controlled release DT tablets were shown clearly. Controlled release matrix-type tablet formulations were prepared using hydroxypropyl methylcellulose (HPMC) (low and high viscosity), Eudragit RS and Carbopol, and the effects of different polymers on DT release from the tablet formulations were investigated. The dissolution rate profiles were compared and analyzed kinetically. An Artificial Neural Network (ANN) model was developed to predict drug release and a successful model was obtained. Subsequently, an optimum formulation was selected and evaluated in terms of its analgesic and anti-inflammatory activity. Although the developed controlled release tablets did not have an initial dose, they were found to be as effective as commercially available tablets on the market. Dissolution and in vivo studies have shown that the prepared tablets were able to release DT for longer time periods, making the tablets more effective, convenient and more tolerable.


Asunto(s)
Comprimidos/análisis , Trometamina/efectos adversos , Administración Oral , Antiinflamatorios no Esteroideos/efectos adversos , Cetoprofeno/agonistas , Dosificación/efectos adversos , Liberación de Fármacos/efectos de los fármacos , Analgésicos/farmacocinética
6.
Belo Horizonte; s.n; 2020. 176 p. ilus, tab.
Tesis en Portugués | BBO, LILACS | ID: biblio-1282951

RESUMEN

A analgesia preemptiva tem como princípio a administração de fármacos antes do início dos estímulos dolorosos, a fim de reduzir ou prevenir a dor pós-operatória. Apesar da sua importância, os efeitos da analgesia preemptiva em cirurgias odontológicas reportados na literatura ainda são conflitantes. Assim, o objetivo deste estudo foi avaliar a eficácia clínica de diferentes classes de medicamentos para analgesia preemptiva, em 2 propostas de investigação 1) cirurgias para exodontia de terceiros molares impactados; 2) cirurgias periodontais a retalho. Para tal, foram realizados ensaios clínicos randomizados placebo-controlados onde os participantes recebiam, 1 hora antes da cirurgia, o medicamento teste e o placebo em cirurgias distintas, em um desenho boca-dividida. Na primeira proposta de investigação, de um total de 376 pacientes com necessidade de exodontia de terceiros molares inferiores classe IIB, foram selecionados 100 pacientes, com idade entre 18 - 30 anos (22,4±2,9), alocados em 5 grupos (n = 20 por grupo), sendo: 1) paracetamol; 2) cetoprofeno; 3) ibuprofeno; 4) nimesulida; 5) dexametasona). Através de escala visual analógica, dor pós-operatória foi avaliada nos tempos 1h, 6h, 12h, 24h, 48h e 72h e edema foi avaliado nos tempos baseline, 24h, 48h, 72h e 7 dias pós-operatórias. As diferenças entre o medicamento de teste e o placebo foram determinadas como a variável de resposta. Um modelo de Equação de Estimativa Generalizada foi ajustado para cada variável desfecho e os grupos foram comparados pelo teste de Tukey. O ibuprofeno e a nimesulida apresentaram efeitos preemptivos gerais mais altos no controle de dor ao longo do tempo, sem diferenças entre eles (p = 0,557). O paracetamol mostrou efeitos gerais mais baixos no controle do edema ao longo do tempo, quando comparado aos outros medicamentos em teste, que mostraram efeitos semelhantes (p<0,05). Também foram observados melhores resultados na quantidade de medicamentos de resgate para o ibuprofeno e a nimesulida, sem diferenças entre eles (p = 0,999). Ibuprofeno e a nimesulida mostraram melhores efeitos preemptivos gerais nas cirurgias de terceiros molares inferiores impactados e assim devem ser considerados caso a caso como medicamentos de escolha em analgesia preemptiva. Na segunda proposta de investigação, de um total de 360 indivíduos com necessidade de cirurgias a retalho, foram selecionados 40 pacientes, com idade entre 18 a 60 anos (43,40 ± 11,91), alocados em 2 grupos (n = 20 por grupo), sendo 1) ibuprofeno; 2) nimesulida. Através da escala visual analógica, dor pós-operatória foi avaliada nos tempos 1h, 6h, 12h, 24h, 48h e 72h. As diferenças entre medicamento teste e placebo foram determinadas como a variável de resposta. Um modelo de Equação de Estimativa Generalizada separado foi ajustado para cada variável desfecho e os grupos foram comparados pelo teste de Tukey. O uso de medicação de resgate foi menor e o tempo pós-operatório foi maior nos grupos teste ibuprofeno e nimesulida em comparação ao placebo (p<0,001). E o grupo nimesulida apresentou escores de EVA mais baixos nos tempos T12, T24, T72 horas (p<0,001; p<0,001; p<0,007), mostrando-se um coadjuvante benéfico para o controle da dor pós-operatória em cirurgias periodontais a retalho.


Preemptive analgesia has as its principle the administration of drugs before the start of painful stimuli, in order to reduce or prevent postoperative pain. Despite its importance, the effects of preemptive analgesia in dental surgeries reported in the literature are still conflicting. Thus, the objective of this study was to evaluate the clinical efficacy of different classes of drugs for preemptive analgesia, in 2 different research proposals: 1) surgeries for extraction of impacted third molars; 2) periodontal flap surgeries. To this end, randomized placebo-controlled clinical trials were carried out where the participants received, 1 hour before surgery, the test drug and the placebo in different surgeries, in a mouth-divided design. In the first research proposal, from a total of 376 patients in need of extraction of lower third molars, class IIB, 100 patients were selected, aged between 18 - 30 years (22.4 ± 2.9), allocated in 5 groups ( n = 20 per group), being: 1) acetaminophen; 2) ketoprofen; 3) ibuprofen; 4) nimesulide; 5) dexamethasone). Through a visual analog scale, postoperative pain was assessed at 1h, 6h, 12h, 24h, 48h and 72h and edema was assessed at baseline, 24h, 48h, 72h and 7 postoperative days. Differences between test drug and placebo were determined as response variable. A separate Generalized Estimation Equation model was separated for each outcome variable and the groups were compared using the Tukey test. Ibuprofen and nimesulide higher overall preemptive sinks in pain controls over time, with no differences between them (p = 0.557). Paracetamol general effects resulting from lower control of edema over time, when compared to other drugs under test, which affect other similar effects (p <0.05). Better results were also observed in the quantity of rescue drugs for ibuprofen and nimesulide, with no differences between them (p = 0.999). It was concluded that ibuprofen and nimesulide are the main general preemptive effects in impacted lower third molar surgeries. Thus, in the decision-making process for preemptive analgesia, ibuprofen and nimesulide should be considered case by case as the drugs of choice. In the second research proposal, from a total of 360 individuals in need of retail surgery, 40 patients were selected, aged between 18 and 60 years (43.40 ± 11.91) years, allocated in 2 groups (n = 20 per group), being 1) ibuprofen; 2) nimesulide. Through the visual analog scale, postoperative pain was assessed at 1h, 6h, 12h, 24h, 48h and 72h. The differences between the test drug and the placebo were determined as the response variable. A separate Generalized Estimation Equation model was separated for each outcome variable and the groups were compared using the Tukey test. The nimesulide group had lower complementary EVA scores at times T12, T24, T72 hours (p <0.001; p <0.001; p <0.007). The use of rescue medication was less secondary and the postoperative time was longer in the ibuprofen and nimesulide test groups compared to placebo (p <0.001). Thus, nimesulide can be considered a beneficial adjunct to the control of postoperative pain in periodontal flap surgeries.


Asunto(s)
Adulto , Cirugía Bucal , Preparaciones Farmacéuticas/análisis , Procedimientos Quirúrgicos Orales , Analgesia , Dexametasona , Ibuprofeno , Cetoprofeno , Hiperalgesia , Acetaminofén
7.
Int. j. morphol ; 37(4): 1572-1577, Dec. 2019. tab
Artículo en Inglés | LILACS | ID: biblio-1040171

RESUMEN

Hypoxia hypobaric (HH) can cause alterations at testicular level, with temperature increase, intrascrotal alteration and deterioration of spermatogenesis. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ketoprofen have anti-angiogenic properties, and can decrease testicular abnormalities. The objective of the study was to evaluate the effect of ketoprofen on spermatogenesis of mice exposed to continuous hypobaric hypoxia. 78 Mus musculus CF-1 male mice 3 to 4 months old were used and subjected to HH in chamber at 4200 m. They were divided into 13 groups (G) of 6 animals: 10 with HH cycles (1, 2, 3, 4 and 8, lasting 8.3 days each cycle, two groups each) and 3 in normoxia (Nx). Intraperitoneal ketoprofen 25 mg/kg was administered every 4 days. Euthanasia of these animals was performed at the end of each cycle and in the case the Nx groups at the end of cycles 1, 4 and 8. Percentage of microhematocrit and reticulocytes were measured in blood smears and a morphometric and histopathological analysis of the height of the epithelium, the tubular diameter and the diameter of the tubular lumen was made. It was shown that hematocrit increases continuously up to 8 cycles, while reticulocytes increase up to 3 cycles. Continuous HH decreases the tubular diameter in a sustained manner and proportional to HH cycles, and the height increased only in the groups subjected to 8 cycles. The groups treated with ketoprofen saw a decrease in angiogenesis, presenting some degree of protection at the testicular level.


La hipoxia hipobárica (HH) puede provocar alteraciones a nivel testicular, con aumento de la temperatura, alteración intraescrotal y deterioro de la espermatogénesis. Los antiinflamatorios no esteroidales (AINEs) como el ketoprofeno tienen propiedades antiangiogénicas, pudiendo disminuir las alteraciones testiculares. El objetivo de estudio fue evaluar el efecto del ketoprofeno en la espermatogénesis de ratones expuestos a hipoxia hipobárica continua. Se utilizaron 78 ratones macho Mus musculus CF-1 de 3 a 4 meses de edad y se sometieron a HH en cámara a 4200 m. Se dividieron en 13 grupos (G) de 6 animales: 10 con ciclos de HH (1, 2, 3, 4 y 8, con duración de 8,3 días cada ciclo, dos grupos cada uno) y 3 en normoxia (Nx). Se administró ketoprofeno intraperitoneal 25 mg/kg cada 4 días. La eutanasia de estos animales se realizó al final de cada ciclo y en el caso los grupos Nx al final de los ciclos 1, 4 y 8. Se midió porcentaje de microhematocrito y reticulocitos en frotis de sangre y se hizo un análisis morfométrico e histopatológico de la altura del epitelio, el diámetro tubular y el diámetro de la luz tubular. Se evidenció que el hematocrito aumenta de manera continua hasta los 8 ciclos, en cambio los reticulocitos aumentan hasta los 3 ciclos. La HH continua disminuye el diámetro tubular de forma sostenida y proporcional a los ciclos de HH, y la altura aumentó sólo en los grupos sometidos a 8 ciclos. Los grupos tratados con ketoprofeno se vio una disminución de la angiogénesis, presentando algún grado de protección a nivel testicular.


Asunto(s)
Animales , Masculino , Ratones , Espermatogénesis/efectos de los fármacos , Testículo/efectos de los fármacos , Antiinflamatorios no Esteroideos/farmacología , Cetoprofeno/farmacología , Hipoxia/fisiopatología , Reticulocitos/efectos de los fármacos , Túbulos Seminíferos/efectos de los fármacos , Testículo/lesiones , Antiinflamatorios no Esteroideos/administración & dosificación , Cetoprofeno/administración & dosificación , Hematócrito , Neovascularización Patológica
8.
Rev. bras. anestesiol ; 69(4): 403-412, July-Aug. 2019. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1041995

RESUMEN

Abstract Background and objectives Intrathecal administration of non-steroidal anti-inflammatory drugs is more efficacious for post-operative pain management. Cyclooxygenase inhibiting non-steroidal anti-inflammatory drugs like (S)-(+)-Ketoprofen, may be effective at lower intrathecal doses than parenteral ones. Preclinical safety regarding possible neurotoxicity associated with the intrathecal (S)-(+)-Ketoprofen was not evaluated. Here we analysed the neurotoxicity of intrathecally administered (S)-(+)-Ketoprofen in rats. Methods A randomized placebo-controlled experimental study was conducted. Sprague-Dawley rats (250-300 g) aged 12-16 weeks were randomly divided into 2 treatments [100 and 800 µg (S)-(+)-Ketoprofen] and control (sterile water) groups. Intrathecal catheters were placed via the atlantoaxial space in anesthetized rats. Pinch-toe tests, motor function evaluations and histopathological examinations of the spinal cord and nerve roots were performed at days 3, 7 and 21. Spinal cord sections were evaluated by light microscopy for the dorsal axonal funiculus vacuolation, axonal myelin loss, neuronal chromatolysis, neuritis, meningeal inflammation, adhesions, and fibrosis. Results Rats in all the groups exhibited normal pinch-toe testing response (score = 0) and normal gait at each observed time (motor function evaluation score = 1). Neurotoxicity was higher with treatments on days 3 and 7 than that on day 21 (2, 3, 0, p = 0.044; 2, 5, 0, p = 0.029, respectively). On day 7, the total scores reflecting neuronal damage were higher in the 800 µg group than those in the 100 µg and Control Groups (5, 3, 0, p = 0.048, respectively). Conclusion Intrathecal (S)-(+)-Ketoprofen caused dose-dependent neurohistopathological changes in rats on days 3 and 7 after injection, suggesting that (S)-(+)-Ketoprofen should not be intrathecally administered.


Resumo Justificativa e objetivos A administração intratecal de anti-inflamatórios não esteroides é mais eficaz no tratamento da dor pós-operatória. Anti-inflamatórios não esteroides, como o (S)-(+)-cetoprofeno, pode ser eficaz em doses intratecais inferiores às parenterais. A segurança pré-clínica relativa à possível neurotoxicidade associada ao (S)-(+)-cetoprofeno intratecal não foi avaliada. Neste estudo avaliamos a neurotoxicidade do (S)-(+)-cetoprofeno administrado por via intratecal em ratos. Métodos Conduzimos um estudo experimental randomizado e controlado por placebo em ratos Sprague-Dawley (250-300 g) com idades entre 12 e 16 semanas. Eles foram randomicamente divididos em dois grupos de tratamento [100 e 800 µg de (S)-(+)-cetoprofeno] e um de controle (água estéril). Cateteres intratecais foram colocados através do espaço atlantoaxial nos ratos anestesiados. Testes de pinça, avaliações da função motora e exames histopatológicos da medula espinhal e das raízes nervosas foram realizados nos dias 3, 7 e 21 do estudo. Os cortes da medula espinhal foram avaliados por microscopia de luz para vacuolização do funículo axonal dorsal, perda de mielina axonal, cromatólise neuronal, neurite, inflamação, aderências e fibrose das meninges. Resultados Em todos os grupos, os ratos exibiram resposta normal ao teste de pinça (pontuação = 0) e marcha normal em cada tempo observado (escore de avaliação da função motora = 1). A neurotoxicidade foi maior com os tratamentos nos dias 3 e 7 do que no dia 21 (2, 3, 0, p = 0,044; 2, 5, 0, p = 0,029, respectivamente). No dia 7, os escores totais refletindo o dano neuronal foram maiores no grupo com 800 µg que nos grupos com 100 µg e controle (5, 3, 0, p = 0,048, respectivamente). Conclusão A administração intratecal de (S)-(+)-cetoprofeno causou alterações neuro-histopatológicas dose-dependentes em ratos nos dias 3 e 7 após a aplicação e sugerindo que o (S)-(+)-cetoprofeno não deve ser administrado por via intratecal.


Asunto(s)
Animales , Masculino , Ratas , Médula Espinal/efectos de los fármacos , Antiinflamatorios no Esteroideos/toxicidad , Cetoprofeno/toxicidad , Síndromes de Neurotoxicidad/etiología , Ratas , Factores de Tiempo , Inyecciones Espinales , Antiinflamatorios no Esteroideos/administración & dosificación , Cetoprofeno/administración & dosificación , Ratas Sprague-Dawley , Relación Dosis-Respuesta a Droga
9.
J. oral res. (Impresa) ; 8(2): 152-158, abr. 30, 2019. tab, ilus
Artículo en Inglés | LILACS | ID: biblio-1145329

RESUMEN

Objective: To evaluate the effects of administering diclofenac and ketoprofen, as well as the effects of environmental oxygen pressure variation on mandibular bone regeneration. Methods: Thirty-six guinea pigs were distributed into two equal groups. Mandibular bone defects were performed on both groups. Group A was monitored under oxygen pressure at altitude (3320msl, 107mm Hg). Group B was monitored at sea level oxygen pressure (150msl, 157mm Hg). Each group was subdivided into 3 equal groups (A1, A2, A3 and B1, B2, B3). Subgroups A1 and B1 were given diclofenac; subgroups A2 and B2 ketoprofen; subgroups A3 and B3 NaCl. Bone regeneration was evaluated histologically on days 15 and 30. Results: After 15 days in the group controlled at sea level, the level of osteoblasts presented by the control subgroup was significantly higher (28.00±2.65) compared to the diclofenac subgroup (16.00±6.25) and to the ketoprofen subgroup (18.00±4.36); (p=0.041). After 15 days in the group controlled at altitude, the level of osteoblasts was significantly higher in the control subgroup (38.00±5.29) compared to the diclofenac subgroup (21.67±6.35) and to the ketoprofen subgroup (19.33±2.52); p=0.007. After 30 days in the group at sea level there was no difference found in the cell counting; p>0.05. After 30 days in the group controlled at altitude, the level of osteoblast was significantly higher in the control subgroup (58.00±4.58) compared to the diclofenac subgroup (34.33±4.73) and the ketoprofen subgroup (34.00±11.14); (p=0.003). Conclusion: The administration of diclofenac and ketoprofen produced lower mandibular bone regeneration, the effect being significantly more negative at sea level.


Objetivo: Evaluar el efecto de la administración de diclofenaco y ketoprofeno y de la variación de la presión de oxígeno ambiental sobre la regeneración ósea mandibular. Métodos: Participaron 36 cobayos distribuidos en dos grupos iguales. A ambos grupos se les realizaron defectos óseos mandibulares. El Grupo A fue controlado bajo presión de oxígeno en altura (3320msnm, 107mm Hg). El Grupo B fue controlado bajo presión de oxígeno a nivel del mar (150msnm, 157mm Hg). Cada grupo fue dividido en 3 subgrupos iguales (A1, A2, A3 y B1, B2, B3). Los subgrupos A1 y B1 recibieron diclofenaco; A2 y B2, ketoprofeno; A3 y B3, NaCl. La regeneración ósea fue evaluada histológicamente a los 15 y 30 días. Resultados: A nivel del mar, a los 15 días, hubo una significativa mayor cantidad de osteoblastos en el subgrupo control (28,00±2,65) comparado con el subgrupo diclofenaco (16,00±6.25) y ketoprofeno (18,00±4.36); (p=0,041). En altura, a los 15 días, hubo una significativa mayor cantidad de osteblastos en el subgrupo control (38,00±5,29) comparado con el subgrupo diclofenaco (21,67±6,35) y ketoprofeno (19,33±2,52); p=0,007. A nivel del mar, a los 30 días, no se encontró diferencia en el conteo celular; p>0,05. En altura, a los 30 días, se encontró una significativa mayor cantidad de osteoblastos en el subgrupo control (58,00±4,58) comparado con el subgrupo diclofenaco (34,33±4,73) y ketoprofeno (34,00±11,14); (p=0,003). Conclusión: La administración de diclofenaco y ketoprofeno produjeron una menor regeneración ósea mandibular, siendo este efecto significativamente más negativo a nivel del mar.


Asunto(s)
Animales , Cobayas , Huesos/efectos de los fármacos , Regeneración Ósea/efectos de los fármacos , Antiinflamatorios no Esteroideos/farmacología , Osteoblastos/efectos de los fármacos , Presión Atmosférica , Diclofenaco/uso terapéutico , Cetoprofeno/uso terapéutico , Factor 1 Inducible por Hipoxia
10.
Bol. méd. postgrado ; 34(1): 7-12, Ene-Jun. 2018. tab, graf
Artículo en Español | LIVECS, LILACS | ID: biblio-1121140

RESUMEN

En cirugía traumatológica y ortopédica se han propuesto la combinación de distintos analgésicos y/o técnicas analgésicas para el tratamiento del dolor postoperatorio. Por esta razón, se realizó un ensayo clínico controlado, no ciego, con una muestra de 40 pacientes cuyo objetivo fue determinar la eficacia analgésica de la combinación Morfina/Dexketoprofeno versus Morfina/Paracetamol en pacientes sometidos a cirugía de miembros inferiores en el Servicio de Traumatología y Ortopedia del Hospital Central Universitario Dr. Antonio María Pineda. Los pacientes fueron distribuidos aleatoriamente en dos grupos: grupo M/D a quienes se les administró 100 mcg de morfina y 50 mg de dexketoprofeno y grupo M/P quienes recibieron 100 mcg de morfina y 1 gr de paracetamol. Ambos grupos reportaron ausencia de dolor en las primeras 6 horas, a las 18 horas 80% del grupo M/D y 100% del grupo M/P mostraron ausencia del dolor mientras que a las 24 horas ambos grupos reportaron dolor leve. Sólo 35% de los pacientes del grupo M/D recibió analgesia de rescate. Los efectos adversos fueron observados en 15% del grupo M/D y 5% del grupo M/P. Las combinaciones Morfina/Dexketoprofeno y Morfina/Paracetamol son seguras y eficaces para disminuir el dolor postoperatorio de los pacientes sometidos a cirugía de miembros inferiores, no obstante este último no requiere analgesia de rescate y los efectos adversos son menores(AU)


In trauma and orthopedic surgery, combination of different analgesics and/or analgesic techniques has been used for treatment of pain after surgery. For this reason, a clinical controlled study with 40 patients was performed to test the analgesic efficiency of the combination Morphine/Dexketoprofen versus Morphine/Paracetamol in patients admitted for lower limb surgery at the Service of Orthopedic Surgery and Orthopedics of the Hospital Central Universitario Dr. Antonio María Pineda. Patients were distributed in two groups: Group M/D which received 100 mcg of morphine and 100 mg of Dexketoprofen and Group M/P which received 100 mcg of morphine and 1 gr of paracetamol. Both groups did not show pain in the first 6 hours, 18 hours post surgery 80% of group M/D and 100% of the group M/P showed absence of pain while 24 hours after both groups reported slight pain. Only 35% of patients of group M/D received rescue analgesia; 15 % of group M/D and 5 % of group M/P showed minor adverse effects. The combination Morphine/Dexketoprofen and Morphine/Paracetamol are effective and safe in diminishing post operatory pain in patients submitted for lower limb surgery; nevertheless, the latter does not need rescue analgesia and has minor adverse effects(AU)


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Traumatología , Cetoprofeno , Procedimientos Ortopédicos , Acetaminofén , Morfina/uso terapéutico , Dolor Postoperatorio , Antiinflamatorios no Esteroideos , Analgesia
11.
Braz. dent. j ; 29(2): 140-149, Mar.-Apr. 2018. tab, graf
Artículo en Inglés | LILACS | ID: biblio-951530

RESUMEN

Abstract In view of the gastrointestinal problems generated by the ketoprofen use, the ketoprofen association with omeprazole is available on the market. However, this association efficacy in acute pain control has not been established. Bilateral extraction of lower third molars in similar positions is currently the most used model for the evaluation and investigation of the efficacy and pharmacological effects of new compounds for the treatment of acute postoperative pain. The randomized and crossover study consisted in evaluating the clinical efficacy of therapy performed by ketoprofen 100 mg (twice daily-b.i.d.) versus ketoprofen 200 mg + omeprazole 20 mg (once daily-q.d.) to pain, swelling and trismus control in the bilateral extraction model of lower third molars in similar positions in two different appointments, in 50 volunteers. Volunteers reported significantly less postoperative pain at various post-operative periods and consumed less rescue analgesic medication (acetaminophen 750 mg) throughout the study when they took the combination of ketoprofen 200 mg + omeprazole 20 mg (q.d.). Following administration of both study drugs, no gastrointestinal adverse reactions were reported by volunteers. Furthermore, the evaluations of the drugs in pain control by the volunteers were significantly favorable to ketoprofen 200 mg + omeprazole 20 mg (q.d.). For swelling and trismus control, the treatments presented similar results. In conclusion, when volunteers took ketoprofen 200 mg + omeprazole 20 mg (q.d.), they reported significantly less postoperative pain at various post-surgical periods and consumed less rescue analgesic medication throughout the study compared with ketoprofen 100 mg (b.i.d).


Resumo Em vista dos problemas gastrointestinais gerados pelo uso do cetoprofeno, a associação do cetoprofeno com o omeprazol está disponível no mercado. No entanto, esta eficácia de associação no controle da dor aguda não foi estabelecida. A extração bilateral de terceiros molares inferiores em posições semelhantes é atualmente o modelo mais utilizado para a avaliação e investigação da eficácia e efeitos farmacológicos de novos compostos para o tratamento da dor aguda pós-operatória. O estudo randomizado e cruzado consistiu na avaliação da eficácia clínica da terapia com cetoprofeno 100 mg (duas vezes ao dia-b.i.d.) versus cetoprofeno 200 mg + omeprazol 20 mg (uma vez ao dia-q.d.) para o controle da dor, do edema e do trismo no modelo bilateral de terceiros molares inferiores em posições semelhantes em duas consultas diferentes, em 50 voluntários. Os voluntários relataram significativamente menos dor pós-operatória em vários períodos pós-operatórios e consumiram menos medicação analgésica de socorro (acetaminofeno 750 mg) durante todo o estudo quando tomaram a combinação de 200 mg de cetoprofeno + 20 mg de omeprazol (q.d.). Após a administração de ambas as drogas do estudo, nenhuma reação adversa gastrointestinal foi relatada pelos voluntários. Além disso, as avaliações das drogas no controle da dor pelos voluntários foram significativamente favoráveis ​​ao cetoprofeno 200 mg + omeprazol 20 mg (q.d.). Para o controle do edema e do trismo, os tratamentos apresentaram resultados semelhantes. Em conclusão, quando os voluntários tomaram 200 mg de cetoprofeno + 20 mg de omeprazol (q.d.), eles relataram significativamente menos dor pós-operatória em vários períodos pós-cirúrgicos e consumiram menos medicação analgésica de socorro durante o estudo comparado com 100 mg de cetoprofeno (b.i.d).


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Adulto Joven , Omeprazol/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Cetoprofeno/uso terapéutico , Manejo del Dolor/métodos , Inflamación/prevención & control , Tercer Molar/cirugía , Trismo/prevención & control , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacocinética , Cetoprofeno/administración & dosificación , Cetoprofeno/farmacocinética , Estudios Cruzados , Quimioterapia Combinada
12.
The Korean Journal of Pain ; : 39-42, 2018.
Artículo en Inglés | WPRIM | ID: wpr-742168

RESUMEN

BACKGROUND: Venipuncture pain is an uncomfortable suffering to the patient. It creates anxiety, fear and dissatisfaction. The ketoprofen transdermal patch is a proven treatment for musculoskeletal and arthritic pain. We planned this study to evaluate the efficacy of the ketoprofen patch to reduce venipuncture pain. METHODS: Two hundred adult patients, aged 18–60 years, of either sex, ASA grade I or II, were enrolled. Presuming that therapy would decrease venipuncture pain by 30%, a power calculation with α = 0.05 and β = 0.80 required enrollment of at least 24 patients into each group. However, 100 patients in each group were recruited. Group I (Control) received a placebo patch; Group II (Ketoprofen) received a 20 mg ketoprofen patch. A selected vein on the dorsum of the patient's non-dominant hand was cannulated with 18 g intravenous cannula 1 h after the application of the respective patch. Assessment of pain was done by a 10 cm visual analogue scale (VAS) of 0–10, where 0 depicts “no pain” and 10 is “the worst imaginable pain”. The venipuncture site was assessed for the presence of skin erythema, swelling and rashes at 12 h, 24 h and at the time of decannulation. RESULTS: Incidence of pain was 100% (94/94) in the control group as compared to 93% (85/91) in the ketoprofen group. The severity of the venipuncture pain was 6 (2) and 2 (2) for control and ketoprofen groups respectively (P < 0.05). CONCLUSIONS: Application of a ketoprofen patch at the proposed site of venipuncture one hour before the attempt is effective and safe for attenuating venipuncture pain.


Asunto(s)
Adulto , Humanos , Ansiedad , Cateterismo , Catéteres , Eritema , Exantema , Mano , Incidencia , Cetoprofeno , Flebotomía , Piel , Parche Transdérmico , Venas , Escala Visual Analógica
13.
Braz. J. Pharm. Sci. (Online) ; 53(4): e00266, 2017. tab, graf, ilus
Artículo en Inglés | LILACS | ID: biblio-889430

RESUMEN

ABSTRACT The aim of this study was to formulate and prepare compression-coated tablets for colonic release (CR-tablets), and to evaluate the bioavailability of ketoprofen following the administration of a single dose from mini-tablets with immediate release (IR-tablets) compared to CR-tablets. CR-tablets were prepared based on time-controlled hydroxypropylmethylcellulose K100M inner compression-coating and pH-sensitive Eudragit® L 30D-55 outer film-coating. The clinical bioavailability study consisted of two periods, in which two formulations were administered to 6 volunteers, according to a randomized cross-over design. The apparent cumulative absorption amount of ketoprofen was estimated by plasma profile deconvolution. CR-tablets were able to delay ketoprofen's release. Compared to IR-tablets used as reference, for the CR-tablets the maximum plasma concentration (Cmax) was lower (4920.33±1626.71 ng/mL vs. 9549.50±2156.12 ng/mL for IR-tablets) and the time needed to reach Cmax (tmax) was 5.33±1.63 h for CR-tablets vs. 1.33±0.88 h for IR-tablets. In vitro-in vivo comparison of the apparent cumulative absorption amount of ketoprofen showed similar values for the two formulations. Therefore, the obtained pharmacokinetic parameters and the in vitro-in vivo comparison demonstrated the reliability of the developed pharmaceutical system and the fact that it is able to avoid the release of ketoprofen in the first part of the digestive tract.


Asunto(s)
Humanos , Adulto , Comprimidos/análisis , Cetoprofeno/administración & dosificación
14.
Arch. pediatr. Urug ; 87(3): 198-209, set. 2016. ilus, tab
Artículo en Español | LILACS | ID: lil-796325

RESUMEN

El dolor es un problema de salud frecuentemente no reconocido e ignorado en pediatría.. Objetivo::reportar la prevalencia de dolor en niños hospitalizados: las 24 horas previas y en el momento de la entrevista. De los pacientes con dolor actual describir: intensidad y tratamiento indicado.. Metodología::estudio transversal, el 6/12/13 en el Centro Hospitalario Pereira Rossell (CHPR) y el 20/1/14 en otras instituciones del país. Se incluyeron los menores de 15 años hospitalizados. Se consideró paciente con dolor cuando el niño o su cuidador referían haberlo experimentado en las 24 horas previas y/o en el momento de la entrevista. Variables: edad, sexo, motivo de ingreso, trastorno cognitivo, tratamiento analgésico indicado, vía e intervalo de administración, tratamiento adyuvante y medidas no farmacológicas. La intensidad se evaluó mediante escalas.. Resultados::se encontraron: 168 niños hospitalizados, 109 en el CHPR; prevalencia de: dolor en las 24 horas previas: 35% (59/168) y en el momento de la encuesta: 15,5% (26/168). De los niños con dolor actual la intensidad era: leve 8/26, moderado 14/26 y severo 4/26. No tenían indicación de fármacos analgésicos: 9/26. El analgésico más indicado fue dipirona (11/17) y la asociación más prescripta: dipirona-ketoprofeno (5/17). Se constató: indicación de intervalo no adecuado: 7/17; vía intravenosa: 12/17; tratamiento adyuvante y medidas no farmacológicas: 1 cada uno.. Conclusiones::se constataron niños hospitalizados con dolor y déficits diversos en los tratamientos indicados. Es necesario que las instituciones sanitarias aborden este problema como parte de su política institucional.


Pain is a health problem often unrecognized and ignored in pediatrics. Objective: to report the prevalence of pain in hospitalized children: 24 hours before and during the interview. To describe intensity and prescribed treatment in patients with current pain. Methods: transversal study, on 06/12/13 at Pereira Rossell Hospital Center (PRHC) and on 20/1/14 in other institutions. Hospitalized children under 15 years old were included. “Patient in pain” was considered when the child or caregiver reported pain experienced in the previous 24 hours and/or at the time of the interview. Variables: age, gender, reason for admission, cognitive disorder, analgesic treatment indicated, route of administration, dosing interval, adjuvant and non-pharmacological treatments. Validated scales were used to assess intensity. Results: 168 hospitalized children, 109 at PRHC; prevalence of pain in the previous 24 hours: 35% (59/168) and during the interview: 15.5% (26/168). Intensity of pain found in children with current pain was: 8/26 mild, 14/26 moderate and 4/26 severe; 9/26 did not have any analgesic prescription. The most prescribed analgesic was: dipirone (11/17) and most prescribed association was: dipirone-ketoprofen (5/17). Interdose interval was inappropriate in 7/17; intravenous route of administration was indicated in 12/17; adjuvant and non-pharmacological treatments were found in one patient each. Conclusions: hospitalized children in pain and several problems in analgesic treatment prescription were found. Institutional policies directed to address this problem in management are needed.


Asunto(s)
Humanos , Masculino , Adolescente , Dimensión del Dolor , Niño Hospitalizado , Manejo del Dolor , Tramadol/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Dipirona/uso terapéutico , Cetoprofeno/uso terapéutico , Epidemiología Descriptiva , Estudios Transversales , Quimioterapia Combinada , Analgésicos Opioides/uso terapéutico
15.
Rev. ciênc. farm. básica apl ; 36(1)mar. 2015. ilus
Artículo en Portugués | LILACS | ID: lil-761229

RESUMEN

O cetoprofeno é um anti-inflamatório não esteroidal, antipirético e analgésico amplamente utilizado na prática clínica para o tratamento de artrite reumatóide e outras doenças inflamatórias. Seu mecanismo de ação está baseado na inibição não seletiva da COX, porém esta inibição também promove alguns efeitos adversos. Diferentes pesquisas demonstram que o estresse oxidativo pode estar relacionado com o aparecimento dos efeitos adversos provocados pelo cetoprofeno. Em contrapartida, diversos estudos apontam a participação do estresse oxidativo no ambiente inflamatório. Portanto, tornou-se promissor o estudo da relação entre o cetoprofeno, a inflamação e o estresse oxidativo. Diante deste fato, o objetivo deste trabalho é revisar a literatura a fim de reunir informações sobre a ação do cetoprofeno diante do estresse oxidativo, presente no processo inflamatório, e o aparecimento dos efeitos adversos provocados pelo uso deste fármaco.(AU)


The ketoprofen is a non steroidal anti-inflammatory, antipyretic and analgesic widely used in clinical practice for the treatment of rheumatoid arthritis and other inflammatory diseases. Its mechanism of action is based on non-selective COX inhibition, but this inhibition also leads to some adverse effects. Different researches have shown that oxidative stress may be associated with the onset of adverse effects caused by ketoprofen. On the other hand, several studies point to the involvement of oxidative stress in the inflammatory environment. Therefore, it has become promising study the relationship between the ketoprofen, inflammation and oxidative stress. Considering this fact, the aim of this paper is to review the literature in order to gather information on the effect of ketoprofen on the oxidative stress present in the inflammatory process, and the appearance of adverse effects of using this drug.(AU)


Asunto(s)
Antiinflamatorios no Esteroideos , Cetoprofeno/efectos adversos , Cetoprofeno/uso terapéutico , Estrés Oxidativo , Inflamación
16.
Rev. bras. enferm ; 67(6): 942-948, Nov-Dec/2014.
Artículo en Portugués | LILACS, BDENF | ID: lil-732806

RESUMEN

O estudo objetivou conhecer o contexto do homem resiliente ao adoecer por câncer de próstata. Trata-se de um estudo de caso etnográfico realizado com dois homens sobreviventes ao câncer de próstata, com alto grau de resiliência. Os dados foram coletados no domicílio, no período de abril e maio de 2012, por meio da entrevista semiestruturada em profundidade, de observação participante e do ecomapa. Pela análise dos dados construíram-se duas unidades de sentido: "Identidade do homem resiliente: contextualizando os informantes" e "O homem resiliente descobrindo-se doente". Apreende-se que a identidade de ser homem resiliente, para estes informantes, foi marcada pela diferença histórica e cultural que permeou as suas ações, no processo de adoecimento por câncer de próstata. Considera-se importante que os enfermeiros atentem para os aspectos culturais da saúde do homem, para que este possa sentir-se parte integrante do processo de cura, tornando-se sujeito ativo frente à própria saúde.


The study aimed to understand the context of resilient man when ill with prostate cancer. This is an ethnographic case study conducted with two prostate cancer survival men with a high degree of resilience. The data was collected on their places, in 2012 April and May, using semi-structured in-depth interviews, participant observation and ecomap. For the data analysis, it was built two units of meaning: "Identity of the resilient man: contextualizing the informants" and "The resilient man finding himself ill". It was noticed that the identity of being a resilient man, to these informants, was marked by historical and cultural difference which permeated their actions in the process of being ill with prostate cancer. It is important that nurses pay attention to the cultural aspects of human health, so that they can feel part of the healing process, becoming an active subject facing their own health.


El estudio enfocó conocer el contexto del hombre resiliente al enfermar por cáncer de próstata. Se trata de un estudio de caso etnográfico realizado con dos hombres sobrevivientes al cáncer de próstata con alto grado de resiliencia. Los datos fueron recogidos en el domicilio, en el período de abril y mayo de 2012, por medio de entrevista semiestructurada en profundidad, observación participante y ecomapa. Por el análisis de los datos, se construyeron dos unidades de sentido: "Identidad del hombre resiliente: contextualizando a los informantes" y "El hombre resiliente descubriéndose enfermo". Se comprende que la identidad de ser hombre resiliente, para estos informantes, fue marcada por la diferencia histórica y cultural que hicieron permeables sus acciones en el proceso de enfermar por cáncer de próstata. Se considera importante que los enfermeros estén atentos a los aspectos culturales de la salud del hombre, para que este se pueda sentir parte integrante del proceso de cura, tornándose sujeto activo frente a la propia salud.


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Antiinflamatorios/efectos adversos , Bencenoacetamidas , Erupciones por Medicamentos/etiología , Ácidos Hidroxámicos/efectos adversos , Cetoprofeno/efectos adversos , Antiinflamatorios/inmunología , Reacciones Cruzadas/inmunología , Ácidos Hidroxámicos/inmunología , Cetoprofeno/inmunología , Pruebas del Parche/métodos
17.
Arq. bras. med. vet. zootec ; 66(5): 1376-1382, Sep-Oct/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-729750

RESUMEN

Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID) has proven to exert anti-inflammatory, anti-proliferative and anti-angiogenic activities in both neoplastic and non-neoplastic conditions. We investigated the effects of this compound on tumor development in Swiss mice previously inoculated with Ehrlich tumor cells. To carry out this study the solid tumor was obtained from cells of the ascites fluid of Ehrlich tumor re-suspended in physiological saline to give 2.5x106 cells in 0.05mL. After tumor inoculation, the animals were separated into two groups (n = 10). The animals treated with ketoprofen 0.1µg/100µL/animal were injected intraperitoneally at intervals of 24h for 10 consecutive days. Animals from the control group received saline. At the end of the experiment the mice were killed and the tumor removed. We analyzed tumor growth, histomorphological and immunohistochemical characteristics for CDC47 (cellular proliferation marker) and for CD31 (blood vessel marker). Animals treated with the ketoprofen 0.1µg/100µL/animal showed lower tumor growth. The treatment did not significantly influence the size of the areas of cancer, inflammation, necrosis and hemorrhage. Moreover, lower rates of tumor cell proliferation were observed in animals treated with ketoprofen compared with the untreated control group. The participation of ketoprofen in controlling tumor malignant cell proliferation would open prospects for its use in clinical and antineoplasic therapy...


O cetoprofeno é uma droga anti-inflamatória não esteroidal (NSAID), que exerce efeito anti-inflamatório, antiproliferativo e antitumoral em condições neoplásicas e não neoplásicas. Foram investigados os efeitos desse composto sobre o desenvolvimento tumoral de camundongos Swiss previamente inoculados com células do tumor de Ehrlich. Para realização deste estudo, o tumor sólido foi obtido a partir de células do fluido ascítico do tumor de Ehrlich suspendido em solução salina fisiológica para se obter 2,5x106 de células em 0,05mL. Após a inoculação do tumor, os animais foram separados em dois grupos (n = 10). Os animais do grupo tratado receberam cetoprofeno 0,1μg/100μL/animal por via intraperitoneal, em intervalos de 24 horas durante 10 dias consecutivos, e o controle 100µL de solução salina. No final do experimento, os animais foram sacrificados, e o tumor removido. Foram analisados o crescimento do tumor e as características histomorfológicas e imunoistoquímicas para CDC47 (marcador de proliferação celular) e para CD31 (marcador de vasos sanguíneos). Os animais tratados com o cetoprofeno 0,1μg/100μL/animal apresentaram menor crescimento do tumor. O tratamento não influenciou significativamente o tamanho das áreas de neoplasia, inflamação, necrose e hemorragia. Em contraste, uma menor taxa de proliferação das células neoplásicas foi observada nos animais tratados com cetoprofeno em comparação com o grupo controle. A participação do cetoprofeno em controlar a proliferação de células neoplásicas abre perspectivas para sua utilização em terapia clínica antineoplásica...


Asunto(s)
Animales , Ratas , Antineoplásicos , Cetoprofeno/administración & dosificación , Neoplasias/veterinaria , Proliferación Celular , Inflamación , Administración del Tratamiento Farmacológico , Ratones
18.
Rev. bras. anestesiol ; 64(4): 221-226, Jul-Aug/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-720468

RESUMEN

BACKGROUND AND OBJECTIVES: A review of all the adjuncts for intravenous regional anaesthesia concluded that there is good evidence to recommend NonSteroidal Anti-Inflammatory agents and pethidine in the dose of 30 mg dose as adjuncts to intravenous regional anaesthesia. But there are no studies to compare pethidine of 30 mg dose to any of the NonSteroidal Anti-Inflammatory agents. METHODS: In a prospective, randomized, double blind study, 45 patients were given intravenous regional anaesthesia with either lignocaine alone or lignocaine with pethidine 30 mg or lignocaine with ketprofen 100 mg. Fentanyl was used as rescue analgesic during surgery. For the first 6 h of postoperative period analgesia was provided by fentanyl injection and between 6 and 24 h analgesia was provided by diclofenac tablets. Visual analogue scores for pain and consumption of fentanyl and diclofenac were compared. RESULTS: The block was inadequate for one case each in lignocaine group and pethidine group, so general anaesthesia was provided. Time for the first dose of fentanyl required for postoperative analgesia was significantly more in pethidine and ketoprofen groups compared to lignocaine group (156.7 ± 148.8 and 153.0 ± 106.0 vs. 52.1 ± 52.4 min respectively). Total fentanyl consumption in first 6 h of postoperative period was less in pethidine and ketoprofen groups compared to lignocaine group (37.5 ± 29.0 mcg, 38.3 ± 20.8 mcg vs. 64.2 ± 27.2 mcg respectively). Consumption of diclofenac tablets was 2.4 ± 0.7, 2.5 ± 0.5 and 2.0 ± 0.7 in the control, pethidine and ketoprofen group respectively, which was statistically not significant. Side effects were not significantly different between the groups. CONCLUSION: Both pethidine and ketoprofen are equally effective in providing postoperative analgesia up to 6 h, without significant difference in the side effects and none of the adjuncts provide significant ...


JUSTIFICATIVA E OBJETIVOS: uma revisão de todos os adjuvantes para anestesia regional intravenosa concluiu que há boas evidências para recomendar os agentes anti-inflamatórios não esteroides e petidina em dose de 30 mg como adjuvantes para anestesia regional intravenosa. Porém, não há estudos que comparem petidina (30 mg) com quaisquer dos agentes anti-inflamatórios não esteroides. MÉTODOS: em um estudo prospectivo, randômico e duplo-cego, 45 pacientes receberam anestesia regional intravenosa com apenas lidocaína ou lidocaína com petidina (30 mg) ou lidocaína com cetoprofeno (100 mg). Fentanil foi usado como analgésico de resgate durante a cirurgia. Durante as seis primeiras horas de pós-operatório, analgesia foi fornecida via injeção de fentanil e, entre seis e 24 horas, analgesia foi fornecida via comprimidos de diclofenaco. Os escores visuais analógicos para dor e do consumo de fentanil e diclofenaco foram comparados. RESULTADOS: o bloqueio foi inadequado para um caso tanto do grupo lidocaína quanto do grupo petidina; portanto, anestesia geral foi administrada. O tempo para a primeira dose necessária de fentanil para analgesia pós-operatória foi significativamente maior nos grupos petidina e cetoprofeno em comparação com o grupo lidocaína (156,7 ± 148,8 e 153,0 ± 106,0 vs. 52,1 ± 52,4 minutos, respectivamente). O consumo total de fentanil nas primeiras seis horas de pós-operatório foi menor nos grupos petidina e cetoprofeno em comparação com o grupo lidocaína (37,5 ± 29,0 mcg, 38,3 ± 20,8 mcg vs. 64,2 ± 27,2 mcg, respectivamente). O consumo de comprimidos de diclofenaco foi de 2,4 ± 0,7, 2,5 ± 0,5 e 2,0 ± 0,7 no grupo controle, petidina e cetoprofeno, respectivamente, o que não foi estatisticamente significante. ...


JUSTIFICACIÓN Y OBJETIVOS: una revisión sobre todos los adyuvantes para la anestesia regional intravenosa concluyó que hay buenas evidencias para recomendar los agentes antiinflamatorios no esteroideos y la petidina en dosis de 30 mg como adyuvantes para la anestesia regional intravenosa. Sin embargo, no hay estudios comparando la petidina (30 mg) con cualesquiera de los agentes antiinflamatorios no-esteroideos. MÉTODOS: en un estudio prospectivo, aleatorizado y doble ciego, 45 pacientes recibieron anestesia regional intravenosa con solamente lidocaína o lidocaína con petidina (30 mg) o lidocaína con ketoprofeno (100 mg). El fentanilo fue usado como analgésico de rescate durante la cirugía. Durante las 6 primeras horas del postoperatorio, la analgesia fue suministrada vía inyección de fentanilo y entre 6 y 24 h, la analgesia fue suministrada vía comprimidos de diclofenaco. Se compararon las puntuaciones visuales analógicas para el dolor y el consumo de fentanilo y diclofenaco. RESULTADOS: el bloqueo fue inadecuado para un caso tanto del grupo lidocaína como del grupo petidina; por tanto, se administró anestesia general. El tiempo para la primera dosis necesaria de fentanilo para analgesia postoperatoria fue significativamente mayor en los grupos petidina y ketoprofeno en comparación con el grupo lidocaína (156,7 ± 148,8 y 153,0 ± 106,0 vs. 52,1 ± 52,4 min, respectivamente). El consumo total de fentanilo en las primeras 6 h del postoperatorio fue menor en los grupos petidina y ketoprofeno en comparación con el grupo lidocaína (37,5 ± 29,0 mcg; 38,3 ± 20,8 mcg vs. 64,2 ± 27,2 mcg, respectivamente). El consumo de comprimidos de diclofenaco fue de 2,4 ± 0,7; 2,5 ± 0,5; y 2 ± 0,7 en el grupo control, petidina y ketoprofeno, respectivamente, lo que no fue estadísticamente significativo. Los ...


Asunto(s)
Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Anestesia de Conducción/métodos , Cetoprofeno/administración & dosificación , Lidocaína/administración & dosificación , Meperidina/administración & dosificación , Adyuvantes Anestésicos/administración & dosificación , Adyuvantes Anestésicos/efectos adversos , Anestesia de Conducción/efectos adversos , Anestesia Intravenosa/efectos adversos , Anestesia Intravenosa/métodos , Anestésicos Locales/administración & dosificación , Anestésicos Locales/efectos adversos , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Método Doble Ciego , Diclofenaco/administración & dosificación , Fentanilo/administración & dosificación , Cetoprofeno/efectos adversos , Lidocaína/efectos adversos , Meperidina/efectos adversos , Dimensión del Dolor , Estudios Prospectivos , Dolor Postoperatorio/prevención & control , Factores de Tiempo
19.
Journal of Islamic Dental Association of Iran [The]-JIDA. 2014; 26 (3): 169-175
en Persa | IMEMR | ID: emr-149686

RESUMEN

Pain relief is important during orthodontic treatment. The aim of this study was to compare the efficacy of ketoprofen and benzocaine chewing gums for pain reduction during fixed orthodontic treatment. Thirty patients aged 15-25 years experiencing orthodontic pain were randomly divided into 3 groups, each receiving one of the experimental chewing gums namely ketoprofen, benzocaine and the placebo. Instructions were given to the pa-tients and they received the gums taking into account the washout period. Patients recorded their degree of pain perception at 2, 6 and 24 hours, and 2, 3 and 7 days using the visual analog scale [0-100]. Friedman and Wilcoxon tests were used to compare the mean pain scores among the 3 groups. The mean pain score decreased over time in both genders and all groups [P =0.017]. The mean pain score recorded in benzocaine group was lower than that in the ketoprofen and placebo groups but a significant difference was only observed between benzocaine and the ketoprofen groups during the first two hours using Friedman and Wil-coxon tests [P=0.042]. Compared to the control group, both ketoprofen and benzocaine chewing gums significantly decreased pain at all time points except for day 7. Ketoprofen and benzocaine gums were both significantly effective for or-thodontic pain reduction


Asunto(s)
Humanos , Masculino , Femenino , Dolor/tratamiento farmacológico , Cetoprofeno , Benzocaína , Goma de Mascar
20.
Pakistan Journal of Pharmaceutical Sciences. 2014; 27 (6): 2227-2235
en Inglés | IMEMR | ID: emr-166820

RESUMEN

Compatibility and stability of the polygeline-based blood plasma expander/plasma substitute Haemaccel with different drug products i.e., Profenid, Stemetil, and Lasix were examined in the context of its potential use in surgical, spinal, septic shock and in circulatory insufficiency, because treatment, safety, acceptability and efficacy of drug product may be affected by drug instability or incompatibility. Therefore, drug stability and compatibility are critical elements in accurate and appropriate delivery of drug therapy to patients. This study was initiated to specifically and critically assess the compatibility of Haemaccel with different drug products with the aim of delivering safe, suitable, acceptable and efficacious administration of two different drug products simultaneously in emergency conditions. All of these different brands of drug products were physically and chemically compatible with Haemaccel and all of the test results were almost similar before and after mixing different drugs in Haemaccel. This study revealed that Lasix, Profenid and Stemetil can be administered/co-administered with Haemaccel safely. Different drug product must be studies in detail before it's co-administration with Haemaccel


Asunto(s)
Cetoprofeno , Urgencias Médicas , Quimioterapia Combinada , Furosemida , Incompatibilidad de Medicamentos , Estabilidad de Medicamentos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA